Merck, AbbVie slip after Reuters reports US House panel probing China clinical trials

AbbVie

30/06/2026 11:16

** Shares of Merck MRK.N fall 1.2% to $127.79 premarket, AbbVie ABBV.N shares marginally down at $252.71
** A U.S. House committee has launched investigations into Merck and AbbVie over their clinical trials in China, including sites in Xinjiang and Chinese military-affiliated hospitals, Reuters reports citing letters 
** Lawmakers ask the companies to provide details on trial oversight, patient protections, data security and due diligence by July 17
** Merck says patient safety and ethical integrity are priorities of its clinical research program and that it follows all global guidelines; AbbVie declines to comment
** Committee says there is no evidence of wrongdoing, but warns that trials in China may pose ethical concerns and risks of sensitive biotechnology knowledge reaching the Chinese military
** As of last close, MRK up 22.9%, ABBV up 11.3% YTD

(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))